Trial reportBlood2006
Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide.
Trial report in Blood, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 45 citations in OpenAlex.
- A Reproducible Sequence-Level Strategy to Enhance Peptide Immunogenicity While Preserving Wild-Type Epitope Recognition.Antibodies (Basel, Switzerland) · 2025Article
- Recent Findings on Therapeutic Cancer Vaccines: An Updated Review.Biomolecules · 2024Review
- Identification of tumor antigens and immune subtypes in lower grade gliomas for mRNA vaccine development.Journal of translational medicine · 2021Article
- Identification of Tumor Antigens and Immune Landscape in Glioblastoma for mRNA Vaccine Development.Frontiers in genetics · 2021Article
- An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia.British journal of cancer · 2020Article
- Novel Survivin Peptides Screened With Computer Algorithm Induce Cytotoxic T Lymphocytes With Higher Cytotoxic Efficiency to Cancer Cells.Frontiers in molecular biosciences · 2020Article
- Melanoma vaccines: clinical status and immune endpoints.Melanoma research · 2019Article
- Article
- Discovery of immunodominant T-cell epitopes reveals penton protein as a second immunodominant target in human adenovirus infection.Journal of translational medicine · 2016Article
- Overview on poly(ADP-ribose) immuno-biomedicine and future prospects.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2016Review
- Analogue peptides for the immunotherapy of human acute myeloid leukemia.Cancer immunology, immunotherapy : CII · 2015Review
- Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia.Leukemia & lymphoma · 2015Review
- Enhancing Human Immunodeficiency Virus-Specific CD8(+) T Cell Responses with Heteroclitic Peptides.Frontiers in immunology · 2015Review
- An unstable Th epitope of P. falciparum fosters central memory T cells and anti-CS antibody responses.PloS one · 2014Article
- Cross-reactivity of T cells and its role in the immune system.Critical reviews in immunology · 2012Review
- Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy.Journal of translational medicine · 2011Article
- Bridging innate and adaptive antitumor immunity targeting glycans.Journal of biomedicine & biotechnology · 2010Review
- Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.Clinical and experimental immunology · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
Heteroclitic peptide modifications increase immunogenicity, allowing generation of cytotoxic T lymphocytes (CTLs) against weakly immunogenic tumor-associated antigens (TAAs). A critical issue is whether T cells generated against heteroclitic peptides retain the ability to recognize and kill tumor cells expressing the original weak TAAs, and whether there is a lower threshold of binding affinity of the native peptides, below which such CTLs can still kill primary tumor cells. To examine this we used a model examining the ability of native and heteroclitic immunoglobulin (Ig)-derived peptides to generate CTLs that can kill chronic lymphocytic leukemia (CLL) cells. We demonstrate that CTLs generated against heteroclitic peptides have enhanced killing of CD40-activated B cells pulsed with either heteroclitic (P < .001) or native peptide (P = .04) and primary CLL cells (P = .01). The novel finding reported here is that the rate-limiting factor appears to be the ability to generate CTLs and that once generated, CTL lysis of primary tumor cells is independent of the binding affinity of the native peptide. These findings have implications for vaccination strategies in malignancies and are currently being further examined in vivo in murine models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.